-
公开(公告)号:US20090148888A1
公开(公告)日:2009-06-11
申请号:US12360470
申请日:2009-01-27
申请人: Clifford Charles Shone , Conrad Padraig Quinn , Keith Alan Foster , John Chaddock , Philip Marks , J. Mark Sutton , Patrick Stancombe , Jonathan Wayne
发明人: Clifford Charles Shone , Conrad Padraig Quinn , Keith Alan Foster , John Chaddock , Philip Marks , J. Mark Sutton , Patrick Stancombe , Jonathan Wayne
IPC分类号: C12P21/04 , C07K14/195 , C12N15/11
CPC分类号: C12N15/62 , A61K38/00 , A61K39/00 , A61K39/08 , A61K47/6415 , A61K47/646 , A61K2039/505 , A61K2039/53 , A61K2039/627 , C07K14/33 , C07K14/475 , C07K14/65 , C07K2319/00 , C07K2319/20 , C07K2319/23 , C07K2319/50 , C07K2319/55 , C07K2319/705 , C07K2319/75 , C12N9/52 , Y02A50/469 , Y10S530/825
摘要: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.
-
公开(公告)号:US10081803B2
公开(公告)日:2018-09-25
申请号:US14117286
申请日:2012-05-16
申请人: John Chaddock , Elaine Harper
发明人: John Chaddock , Elaine Harper
IPC分类号: C12N9/12 , C12N9/88 , C12N1/20 , C12N15/00 , C12P21/04 , C12P21/06 , C07H21/04 , A61K38/43 , C07K1/00 , C12N9/96 , C07K7/18 , C07K7/23 , C07K14/575 , C12N9/52 , C12N15/62 , C07K14/60 , C12N9/50 , A61K38/00
CPC分类号: C12N9/96 , A61K38/00 , C07K7/18 , C07K7/23 , C07K14/575 , C07K14/57572 , C07K14/60 , C07K2319/00 , C07K2319/06 , C07K2319/21 , C07K2319/50 , C07K2319/74 , C12N9/50 , C12N9/52 , C12N15/62
摘要: The present invention relates to the construction of a new class of Targeted Secretion Inhibitors (TSIs), which comprise a non-cytotoxic protease, translocation peptide and a targeting moiety peptide, wherein the targeting moiety peptide has a free N-terminal domain and a free C-terminal domain; to a single-chain fusion protein precursor thereof, and to a method of activating said single-chain fusion protein precursor.
-
公开(公告)号:US20090004174A1
公开(公告)日:2009-01-01
申请号:US11792076
申请日:2005-12-01
IPC分类号: C12N9/50 , C07K14/00 , C12N15/11 , C12N15/62 , C12P21/02 , A61K38/48 , A61P37/00 , A61P19/00 , A61P9/00 , A61P1/00
CPC分类号: C12N9/50 , A61K38/00 , C07K14/33 , C07K2319/06 , C07K2319/50 , C12N15/62
摘要: The invention provides a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a target cell; a Targeting Moiety that is capable of binding to a Binding Site on the target cell, which Binding Site is capable of undergoing endocytosis to be incorporated into an endocome within the target cell; a protease cleaving site at which site the fusion protein is cleavable by the protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and the translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the target cell.
摘要翻译: 本发明提供了一种单链多肽融合蛋白,其包含:非细胞毒性蛋白酶或其片段,所述蛋白酶或蛋白酶片段能够切割靶细胞的胞外融合装置的蛋白质; 能够结合靶细胞上的结合位点的靶向物质,所述结合位点能够经历内吞作用以掺入靶细胞内的内皮细胞; 蛋白酶切割位点,其中融合蛋白可被蛋白酶切割,其中蛋白酶切割位点位于非细胞毒性蛋白酶或其片段与靶向部位之间; 以及能够将位于内体内的蛋白酶或蛋白酶片段穿过体内膜并进入靶细胞的胞质溶胶的易位结构域。
-
54.
公开(公告)号:US20080152667A1
公开(公告)日:2008-06-26
申请号:US11808057
申请日:2007-06-06
CPC分类号: A61K38/4886 , A61K47/62 , C07K14/33 , C07K2319/33
摘要: A method of treating mucus hypersecretion, the causative factor in chronic obstructive pulmonary disease (COPD), asthma and other clinical conditions involving COPD, comprises administering a compound that inhibits exocytosis in mucus secreting cells or neurones that control or direct mucus secretion. Also described is a compound, for use in the treatment of hypersecretion of mucus, which inhibits mucus secretion by inhibiting mucus secretion by mucus secreting cells, and/or inhibiting neurotransmitter release from neuronal cells controlling or directing mucus secretion.
摘要翻译: 一种治疗粘液分泌过多症的方法,慢性阻塞性肺疾病(COPD),哮喘和其它涉及COPD的临床病症的因素包括给予抑制或分泌粘液分泌细胞或神经元中的胞吐作用的化合物。 还描述了一种用于治疗粘液分泌过高的化合物,其通过抑制由分泌分泌细菌的粘液分泌而抑制粘液分泌,和/或抑制神经递质从控制或引导粘液分泌的神经元细胞释放。
-
公开(公告)号:US07192596B2
公开(公告)日:2007-03-20
申请号:US10241596
申请日:2002-09-12
申请人: Clifford Charles Shone , Conrad Padraig Quinn , Keith Alan Foster , John Chaddock , Philip Marks , J. Mark Sutton , Patrick Stancombe , Jonathan Wayne
发明人: Clifford Charles Shone , Conrad Padraig Quinn , Keith Alan Foster , John Chaddock , Philip Marks , J. Mark Sutton , Patrick Stancombe , Jonathan Wayne
CPC分类号: A61K39/08 , A61K38/00 , A61K39/00 , A61K47/6415 , A61K47/646 , A61K2039/505 , A61K2039/53 , A61K2039/627 , C07K14/33 , C07K2319/00 , C07K2319/20 , C07K2319/23 , C07K2319/50 , C07K2319/55 , C07K2319/705 , C07K2319/75 , C12N9/52 , C12N15/62 , Y10S530/825
摘要: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.
-
-
-
-